Latest Strategy News

Vinyl Group Ltd reported a striking 190% revenue increase for FY2025 but remains deep in the red with a $15.8 million loss. The company’s recent acquisitions and ongoing audit spotlight a pivotal moment for its future.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.

Oliver's Real Food reported a 25.8% increase in net loss to $2.91 million for FY2025 despite a 23.5% rise in core earnings before impairments, driven by operational restructuring and store closures.

SportsHero Limited reported a 189% revenue increase to AU$37,666 for FY25, driven by strategic partnerships across Southeast Asia, despite a continuing loss of nearly AU$2 million. The company secured major telco collaborations and expanded its gaming product footprint in Indonesia and the Philippines.

Janus Electric Holdings reported a steep 94% rise in net loss to $8.7 million for FY2025, impacted by a disruptive battery recall and significant restructuring costs. The company completed a reverse takeover, raised $8.8 million, and secured a $5 million MOU for African expansion, signaling a bold shift toward heavy transport electrification.

Rhythm Biosciences has significantly reduced its annual loss by 44%, boosted by a 91% rise in other income, while launching a new wholly owned subsidiary, RHY GeneType Pty Ltd.

Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.

Havilah Resources reports significant progress on its copper-gold-cobalt projects, including promising drilling outcomes and a $2 million share placement to support ongoing development and exploration.

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.